Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, announced an agreement with Tokyo-based SCRUM Inc. to expand its presence in Japan’s research community. This collaboration will provide researchers in academia and industry with full access to Parse’s innovative single cell sequencing solutions.
“Biotech, pharma, and academic researchers throughout Asia are rapidly adopting Parse’s Evercode single cell sequencing solutions because of their scalability and simplicity,” said Alex Rosenberg, PhD, CEO and co-founder of Parse Biosciences. “By partnering with SCRUM, we are ensuring that researchers in Japan can easily leverage Parse’s advanced single cell sequencing technology to accelerate their discoveries.”
Through this agreement, SCRUM will distribute Parse’s comprehensive portfolio of single cell solutions throughout Japan, including:
- Evercode™ Cell and Nuclei Fixation
- Evercode™ Whole Transcriptome
- Evercode™ TCR
- Evercode™ BCR
- CRISPR Detect
- Gene Select
- Trailmaker™ for simplified single cell data analysis
Also Read: Boehringer Ingelheim Launches ‘One Medicine Platform’ with Veeva Cloud Integration
This partnership builds on Parse’s ongoing expansion in key international markets, including South Korea, Singapore, and India, alongside strong growth in North America, Europe, Australia, Israel, and New Zealand.
“Japan is at the forefront of single cell research, with many researchers making influential contributions to the field,” said Kenji Nishimoto, President of SCRUM. “Our partnership with Parse Biosciences will provide Japan’s researchers with unprecedented access to cutting-edge single cell sequencing technologies, empowering them to achieve impactful scientific breakthroughs.”
SOURCE: BusinessWire
